Abstract: Provided are electrochemically active composite materials that include a first composition optionally of Li1+aMO2+b (Formula I) where ?0.3?a?0.3 and ?0.3?b?1.3 and where M optionally includes 30 at % to 80 at % Mn and 30 at % to 75 at % Ni, the first composition formed of a polycrystalline morphology having a plurality of crystallites and a grain boundary between adjacent crystallites, the grain boundary including one or more enrichment elements, said one or more enrichment elements present at a higher atomic percentage than in an adjacent crystallite, wherein the one or more enrichment elements is selected from the group consisting of Co, Al, or both Co and Al; and a second composition optionally of Li1+cM?2O4+d (Formula II) where ?0.1?c?0.3 and ?0.2?d?0.2, wherein M? comprises Mn at about 75 at % to about 100 at %, wherein the second composition or a portion thereof optionally has a polyhedral morphology; the second composition within, on or about a surface of, or intermixed with said first composition.

Abstract: A lead device is provided for a medical treatment apparatus, where the lead device includes mechanisms for anchoring the lead device in tissue.

Abstract: A brake booster assembly having a brake booster body and a pushrod as well as a pushrod-pedal coupler are provided. The pushrod travels along a pushrod axis when being pushed. The brake booster assembly includes a pushrod-pedal coupler. The pushrod-pedal coupler comprises a pushrod-attachment end arranged on the pushrod and defining a longitudinal axis parallel to the pushrod axis. A pedal-attachment end is configured to be attached to a pedal and having a pedal pivot axis around which the pedal pivots when being pushed. The pedal pivot axis extends across the longitudinal axis. A coupler hinge is arranged between the pushrod-attachment end and the pedal-attachment end and connects the pushrod-attachment end with the pedal-attachment end. The coupler hinge has a coupler hinge axis that extends across the longitudinal axis and the pedal pivot axis. The pedal pivot axis and the coupler hinge axis are offset along the longitudinal axis.

Abstract: A mobile interface cart including a storage tank for receiving effluent from a dialysis (e.g., hemodialysis) procedure and a pump for pumping the effluent from the storage tank to an external waste drain located in the treatment center. In use, the pump enables the effluent to be moved over greater distances and/or around obstacles thereby eliminating, or at least minimizing, the need to construct expensive and time-consuming waste drains in the treatment center.

Abstract: The disclosure includes technology for determining a dimension describing one or more of an event and pattern for an instrument, parsing instrument data of the instrument for occurrences of the dimension at certain points in the instrument data, determining historical value statistics for a set of time intervals relative to the occurrences of the dimension; automatically generating one or more regions for a computer display indicating a graphical probability map representing a graphical performance prediction relative to a point in time of the instrument data based on the historical value statistics; automatically generating a graphical data visualization overlaying the graphical probability map representing the graphical performance prediction relative to the point in time with the instrument data, the one or more regions of the computer display visually indicating the graphical probability map; and providing the graphical data visualization for display on the computer display to a user.

Abstract: A mobile interface cart including a storage tank for receiving effluent from a dialysis (e.g., hemodialysis) procedure and a pump for pumping the effluent from the storage tank to an external waste drain located in the treatment center. In use, the pump enables the effluent to be moved over greater distances and/or around obstacles thereby eliminating, or at least minimizing, the need to construct expensive and time-consuming waste drains in the treatment center.

Abstract: A brake booster assembly having a brake booster body and a pushrod as well as a pushrod-pedal coupler are provided. The pushrod travels along a pushrod axis when being pushed. The brake booster assembly includes a pushrod-pedal coupler. The pushrod-pedal coupler comprises a pushrod-attachment end arranged on the pushrod and defining a longitudinal axis parallel to the pushrod axis. A pedal-attachment end is configured to be attached to a pedal and having a pedal pivot axis around which the pedal pivots when being pushed. The pedal pivot axis extends across the longitudinal axis. A coupler hinge is arranged between the pushrod-attachment end and the pedal-attachment end and connects the pushrod-attachment end with the pedal-attachment end. The coupler hinge has a coupler hinge axis that extends across the longitudinal axis and the pedal pivot axis. The pedal pivot axis and the coupler hinge axis are offset along the longitudinal axis.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: An event data and location-linked spherical imaging system including a spherical imager configured for capturing a spherical image with an action; a localization device collocated with the spherical imager, the localization device configured for providing a location of the spherical imager; a level collocated with the spherical imager, the level configured for indicating an imaging level of the spherical imager; an event data receiver configured for receiving event data from a user, the event data is associated with one or more points of interest on the spherical image; and a compass configured for providing an orientation of the spherical imager in capturing the spherical image, wherein the orientation and location-linked event data is accessible within the context of the spherical image. In one embodiment, the spherical imager includes no more than two imagers. In one embodiment, the action is a single capture.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.

Abstract: The disclosure includes technology for analyzing financial instrument data and generating a forecast. An example method receives financial instrument data for a financial instrument; determines a financial dimension; parses the financial instrument data for occurrences of the financial dimension; computes historical price statistics for a set of time intervals relative to occurrences of the financial dimension; and generates pricing forecast relative to a point in time based on the historical price statistics.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: An event data and location-linked spherical imaging system including a spherical imager configured for capturing a spherical image with an action; a localization device collocated with the spherical imager, the localization device configured for providing a location of the spherical imager; a level collocated with the spherical imager, the level configured for indicating an imaging level of the spherical imager; an event data receiver configured for receiving event data from a user, the event data is associated with one or more points of interest on the spherical image; and a compass configured for providing an orientation of the spherical imager in capturing the spherical image, wherein the orientation and location-linked event data is accessible within the context of the spherical image. In one embodiment, the spherical imager includes no more than two imagers. In one embodiment, the action is a single capture.

Abstract: Disclosed herein are compositions and methods for treating cancer in a subject. This involves administering an oncolytic virus containing a heterologous DNA sequence encoding one or more immunomodulatory and/or immunostimulatory polypeptide(s) of interest to the subject under conditions effective to enhance an anti-tumor immune response in the subject, and to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses.

Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.